vs

Side-by-side financial comparison of ChargePoint Holdings, Inc. (CHPT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $105.7M, roughly 1.4× ChargePoint Holdings, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -49.7%, a 44.1% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 6.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-23.6M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -4.5%).

ChargePoint Holdings, Inc. is an American electric vehicle infrastructure company based in Campbell, California. ChargePoint operates the largest online network of independently owned EV charging stations operating in 14 countries and makes some of its technology.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CHPT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.4× larger
TARS
$151.7M
$105.7M
CHPT
Growing faster (revenue YoY)
TARS
TARS
+122.3% gap
TARS
128.4%
6.1%
CHPT
Higher net margin
TARS
TARS
44.1% more per $
TARS
-5.5%
-49.7%
CHPT
More free cash flow
TARS
TARS
$36.5M more FCF
TARS
$13.0M
$-23.6M
CHPT
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-4.5%
CHPT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CHPT
CHPT
TARS
TARS
Revenue
$105.7M
$151.7M
Net Profit
$-52.5M
$-8.4M
Gross Margin
30.7%
Operating Margin
-42.0%
-5.3%
Net Margin
-49.7%
-5.5%
Revenue YoY
6.1%
128.4%
Net Profit YoY
32.4%
63.8%
EPS (diluted)
$-2.23
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHPT
CHPT
TARS
TARS
Q4 25
$105.7M
$151.7M
Q3 25
$98.6M
$118.7M
Q2 25
$97.6M
$102.7M
Q1 25
$101.9M
$78.3M
Q4 24
$99.6M
$66.4M
Q3 24
$108.5M
$48.1M
Q2 24
$107.0M
$40.8M
Q1 24
$115.8M
$27.6M
Net Profit
CHPT
CHPT
TARS
TARS
Q4 25
$-52.5M
$-8.4M
Q3 25
$-66.2M
$-12.6M
Q2 25
$-57.1M
$-20.3M
Q1 25
$-58.8M
$-25.1M
Q4 24
$-77.6M
$-23.1M
Q3 24
$-68.9M
$-23.4M
Q2 24
$-71.8M
$-33.3M
Q1 24
$-94.7M
$-35.7M
Gross Margin
CHPT
CHPT
TARS
TARS
Q4 25
30.7%
Q3 25
31.2%
Q2 25
28.7%
Q1 25
28.2%
Q4 24
22.9%
Q3 24
23.6%
Q2 24
22.1%
Q1 24
19.3%
Operating Margin
CHPT
CHPT
TARS
TARS
Q4 25
-42.0%
-5.3%
Q3 25
-59.8%
-12.2%
Q2 25
-55.1%
-21.6%
Q1 25
-53.9%
-33.5%
Q4 24
-68.4%
-36.8%
Q3 24
-57.8%
-52.3%
Q2 24
-62.7%
-81.6%
Q1 24
-80.2%
-136.5%
Net Margin
CHPT
CHPT
TARS
TARS
Q4 25
-49.7%
-5.5%
Q3 25
-67.1%
-10.6%
Q2 25
-58.5%
-19.8%
Q1 25
-57.7%
-32.1%
Q4 24
-77.9%
-34.8%
Q3 24
-63.5%
-48.7%
Q2 24
-67.1%
-81.6%
Q1 24
-81.8%
-129.4%
EPS (diluted)
CHPT
CHPT
TARS
TARS
Q4 25
$-2.23
$-0.17
Q3 25
$-2.85
$-0.30
Q2 25
$-0.12
$-0.48
Q1 25
$-5.83
$-0.64
Q4 24
$-3.56
$-0.57
Q3 24
$-3.22
$-0.61
Q2 24
$-0.17
$-0.88
Q1 24
$-23.36
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHPT
CHPT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$180.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$38.4M
$343.4M
Total Assets
$848.0M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHPT
CHPT
TARS
TARS
Q4 25
$180.5M
$417.3M
Q3 25
$194.1M
$401.8M
Q2 25
$195.9M
$381.1M
Q1 25
$224.6M
$407.9M
Q4 24
$219.4M
$291.4M
Q3 24
$243.3M
$317.0M
Q2 24
$261.9M
$323.6M
Q1 24
$327.4M
$298.5M
Total Debt
CHPT
CHPT
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
CHPT
CHPT
TARS
TARS
Q4 25
$38.4M
$343.4M
Q3 25
$70.7M
$335.1M
Q2 25
$118.6M
$332.6M
Q1 25
$137.5M
$342.5M
Q4 24
$181.0M
$224.5M
Q3 24
$230.9M
$237.5M
Q2 24
$277.9M
$252.2M
Q1 24
$327.7M
$275.2M
Total Assets
CHPT
CHPT
TARS
TARS
Q4 25
$848.0M
$562.2M
Q3 25
$870.3M
$534.6M
Q2 25
$897.6M
$495.0M
Q1 25
$898.2M
$500.8M
Q4 24
$966.3M
$377.0M
Q3 24
$1.0B
$376.3M
Q2 24
$1.1B
$376.8M
Q1 24
$1.1B
$349.3M
Debt / Equity
CHPT
CHPT
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHPT
CHPT
TARS
TARS
Operating Cash FlowLast quarter
$-22.5M
$19.3M
Free Cash FlowOCF − Capex
$-23.6M
$13.0M
FCF MarginFCF / Revenue
-22.3%
8.6%
Capex IntensityCapex / Revenue
1.0%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.6M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHPT
CHPT
TARS
TARS
Q4 25
$-22.5M
$19.3M
Q3 25
$-6.2M
$18.3M
Q2 25
$-33.0M
$-29.4M
Q1 25
$-2.7M
$-20.7M
Q4 24
$-30.6M
$-22.2M
Q3 24
$-51.2M
$-8.7M
Q2 24
$-62.5M
$-14.4M
Q1 24
$-41.5M
$-37.8M
Free Cash Flow
CHPT
CHPT
TARS
TARS
Q4 25
$-23.6M
$13.0M
Q3 25
$-7.5M
$16.3M
Q2 25
$-34.0M
$-30.4M
Q1 25
$-4.6M
$-21.2M
Q4 24
$-33.4M
$-22.3M
Q3 24
$-55.0M
$-8.9M
Q2 24
$-66.0M
$-15.4M
Q1 24
$-46.2M
$-38.0M
FCF Margin
CHPT
CHPT
TARS
TARS
Q4 25
-22.3%
8.6%
Q3 25
-7.6%
13.8%
Q2 25
-34.9%
-29.6%
Q1 25
-4.5%
-27.1%
Q4 24
-33.5%
-33.5%
Q3 24
-50.7%
-18.6%
Q2 24
-61.7%
-37.8%
Q1 24
-39.9%
-137.5%
Capex Intensity
CHPT
CHPT
TARS
TARS
Q4 25
1.0%
4.2%
Q3 25
1.3%
1.6%
Q2 25
1.1%
1.0%
Q1 25
1.9%
0.8%
Q4 24
2.8%
0.1%
Q3 24
3.5%
0.6%
Q2 24
3.2%
2.5%
Q1 24
4.1%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHPT
CHPT

Products$56.4M53%
License And Service$42.0M40%
Other$7.3M7%

TARS
TARS

Segment breakdown not available.

Related Comparisons